Sigounas Dimitrios E, Krystallis Christoforos, Couper Graeme, Paterson-Brown Simon, Tatsioni Athina, Plevris John N
Centre for Liver and Digestive Disorders, University of Edinburgh, Edinburgh, UK.
University Department of Surgery, The Royal Infirmary of Edinburgh, Edinburgh, UK.
United European Gastroenterol J. 2017 Feb;5(1):21-31. doi: 10.1177/2050640616650786. Epub 2016 Jun 23.
Self-expandable metal stents (SEMSs) are the main palliative modality used in inoperable oesophageal cancer. Other palliative modalities, including argon plasma coagulation (APC), have also been used.
The purpose of this study was to assess the relative efficacy of SEMS and APC regarding the survival of patients with inoperable oesophageal cancer, not receiving chemo/radiotherapy.
Single centre, retrospective analysis of all patients ( = 228) with inoperable oesophageal cancer between January 2000 and July 2014, not receiving chemo-radiotherapy, treated with SEMS ( = 160) or APC ( = 68) as primary palliation modalities. Cox regression analysis was performed to identify individual factors affecting survival and Kaplan-Meier curves were created for patients treated with APC and SEMS for stage III and IV disease. Survival intervals were compared by the log-rank test.
Type of treatment was the only statistically significant factor affecting survival, after disease stage stratification (hazard ratio (HR): 1.36, 95% confidence interval (CI): 1.13-1.65 of SEMS over APC, : 0.002). Median survival for patients treated with APC and SEMS was 257 (interquartile range (IQR): 414, 124) and 151 (IQR: 241, 61) days respectively in stage III disease. It was 135 (IQR: 238, 43) and 70 (IQR: 148, 32) days respectively in stage IV disease. Both differences were statistically significant ( = 0.02 and 0.05 respectively).
APC is a promising palliation modality in inoperable oesophageal cancer, when patients are not candidates for chemo-radiotherapy. A randomized controlled trial will be needed to confirm those results.
自膨式金属支架(SEMS)是不可切除食管癌的主要姑息治疗方式。其他姑息治疗方式,包括氩等离子体凝固术(APC),也已被使用。
本研究的目的是评估SEMS和APC对未接受化疗/放疗的不可切除食管癌患者生存情况的相对疗效。
对2000年1月至2014年7月期间所有未接受化疗放疗、以SEMS(n = 160)或APC(n = 68)作为主要姑息治疗方式的不可切除食管癌患者(n = 228)进行单中心回顾性分析。进行Cox回归分析以确定影响生存的个体因素,并为III期和IV期疾病接受APC和SEMS治疗的患者绘制Kaplan-Meier曲线。通过对数秩检验比较生存间隔。
在疾病分期分层后,治疗类型是影响生存的唯一具有统计学意义的因素(风险比(HR):SEMS相对于APC为1.36,95%置信区间(CI):1.13 - 1.65,P = 0.002)。III期疾病中接受APC和SEMS治疗的患者中位生存期分别为257天(四分位间距(IQR):414,124)和151天(IQR:241,61)。IV期疾病中分别为135天(IQR:238,43)和70天(IQR:148,32)。两者差异均具有统计学意义(分别为P = 0.02和0.05)。
当患者不适合化疗放疗时,APC是不可切除食管癌一种有前景的姑息治疗方式。需要进行随机对照试验来证实这些结果。